Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.34 |
| ▸ | TSHR | P16473 | 2/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.34 |
| ▸ | MPO | P05164 | 1/20 | 0.34 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | PDE5A | O76074 | 1/20 | 0.31 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.30 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20112463 | 0.80 | SMN1; SMN2 (0.35) | LMNAALDH1A1SMN1; SMN2 | |
| SCHEMBL20112460 | 0.72 | CNR1 (0.33) | LMNATSHRALDH1A1SMN1; SMN2 | |
| SCHEMBL25026161 | 0.69 | ALDH1A1 (0.41) | LMNATSHRALDH1A1SMN1; SMN2TDP1 | |
| SCHEMBL10172918 | 0.65 | SMN1; SMN2 (0.59) | LMNAALDH1A1SMN1; SMN2 | |
| SCHEMBL22670053 | 0.64 | MEN1 (0.39) | LMNAALDH1A1TDP1 | |
| SCHEMBL10080929 | 0.64 | KDM5B (0.43) | KDM5B | |
| SCHEMBL12374075 | 0.64 | LNPEP (0.32) | LMNAALDH1A1TDP1 | |
| SCHEMBL24377276 | 0.63 | CYP1A2 (0.47) | LMNAALDH1A1SMN1; SMN2TDP1 | |
| SCHEMBL22427786 | 0.63 | LMNA (0.41) | LMNAALDH1A1SMN1; SMN2 | |
| SCHEMBL24730800 | 0.63 | LMNA (0.37) | LMNASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210094968-A1 | COMPOSITIONS AND METHODS OF MODULATING SHORT-CHAIN DEHYDROGENASE ACTIVITY | BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM | 2021-04-01 | — | — | US | disclosed |
| US-20180118756-A1 | COMPOSITIONS AND METHODS OF MODULATING SHORT-CHAIN DEHYDROGENASE ACTIVITY | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2018-05-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210094968-A1 | COMPOSITIONS AND METHODS OF MODULATING SHORT-CHAIN DEHYDROGENASE ACTIVITY | HPGD, GCDH, HPGDS | LMNA 1481/4885TSHR 4191/4885ALDH1A1 126/4885 |
| US-20180118756-A1 | COMPOSITIONS AND METHODS OF MODULATING SHORT-CHAIN DEHYDROGENASE ACTIVITY | HPGD, GCDH, HPGDS | LMNA 1481/4885TSHR 4191/4885ALDH1A1 126/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.